Summary#
This bill would change drug labeling rules so labels must show the original manufacturer and other supply-chain details for active ingredients and finished drug products. It adds a unique facility identifier and allows a link, barcode, or QR code to a searchable electronic portal instead of printing all details on the package. The bill also exempts finished drug products meeting these labeling rules from a separate U.S. customs country-of-origin marking requirement.
- Main change: Labels for finished drugs must name the original manufacturer of each active pharmaceutical ingredient (API), the original manufacturer of the finished drug, and the packer or distributor, or provide a link/QR code to a portal with that information.
- APIs: If an API is supplied, its label and certificate of analysis must include the original manufacturer's name, place of business, and unique facility identifier.
- Identifier and access: Labels must include a unique facility identifier for the named firms or give access to a searchable electronic portal containing that information.
- Paper copies: Manufacturers must provide the information in a package insert or a paper copy on request.
- Timing and rules: The Secretary (the FDA) must issue implementing regulations; they take effect no sooner than one year after the final rule and apply to drugs made on or after that date.
- Customs change: If a finished drug is labeled this way, it would not have to meet the usual customs country-of-origin marking rules.
What it means for you#
- Manufacturers (finished drug makers): Must identify the original manufacturer of the finished product and each API used, include a unique facility identifier, or provide a scannable link to that information. They must make information available electronically and in paper upon request.
- API producers: Must have their name, place of business, and a unique facility identifier on any accompanying label and certificate of analysis if they are the "original manufacturer."
- Packers and distributors: If named on labeling, they must supply their identifying information or be included in the portal or printed insert.
- Importers and exporters: Finished drug imports that meet the new labeling format can be exempt from the usual country-of-origin marking requirement.
- Pharmacies, hospitals, and wholesalers: May see changes in packaging and inserts. They could use the added information to trace sources during recalls or quality checks.
- Consumers and patients: May be able to scan a barcode/QR code to see where a drug or its ingredients were made. Paper copies must be provided on request.
- Regulators (FDA and customs): Must write rules to implement the requirements and enforce compliance. Customs may treat covered drugs differently for marking rules.
Expenses#
No plain dollar estimate is provided in the bill text or the supplied material.
- No publicly available information.
- Possible costs that follow from the bill’s requirements could include: updating labels and packaging, adding QR codes or links, creating or linking to searchable portals, staff time to track original manufacturers and UFIs, updating certificates of analysis for APIs, and responding to paper-copy requests.
- Government costs could include time and staff to write and enforce regulations and to handle compliance questions. The bill does not include a fiscal estimate or funding provision.
Proponents' View#
- The bill appears intended to increase transparency and traceability in the drug supply chain by making it easier to see who originally manufactured a drug or its ingredients.
- Supporters may argue this could improve accountability and help trace problems during recalls or quality failures.
- Allowing electronic links, QR codes, or portals could let manufacturers provide more detailed supply-chain data without crowding physical packaging.
- The customs exemption could reduce conflicting labeling requirements for imported finished drugs that already meet the bill’s disclosure rules.
Opponents' View#
- One concern is that the bill does not explain how to protect trade secrets or confidential commercial information about supply chains. Listing original manufacturers publicly could reveal sensitive sourcing details.
- The bill does not define what system must be used for the “unique facility identifier,” leaving uncertainty about standards and interoperability.
- Implementation could create costs for manufacturers, especially smaller firms, from changing labels, updating certificates, and building or linking to portals.
- Relying on QR codes or electronic portals may disadvantage people without smartphones or internet access, though paper copies must be available on request.
- It is unclear who must run or maintain the “searchable electronic portal,” how its accuracy will be checked, or how enforcement and penalties would work.